Evaluation of the Efficacy and Tolerability of the Tested Formula BID After 3 Months in the Treatment of Facial Hyperpigmentation of 3 Origins Melasma, Acne Induced Post-Inflammatory Hyperpigmentation and Solar Lentigo

Led by Cosmetique Active International · Updated on 2024-07-12

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

The objective of this study is to evaluate the efficacy, cosmetic acceptability and improvement of the stigmatization of the tested product (2039125 03) used bis in die (BID) for 3 months in adult patients suffering from mild to moderate melasma, or mild to moderate acne induced post-inflammatory hyperpigmentation, or solar lentigo.

CONDITIONS

Brief Title

Efficacy and Tolerability of the Tested Formula After 3 Months in Treatment of Facial Hyperpigmentation of 3 Origins

Who Can Participate

Age: 18Years +

All Genders

Healthy Volunteers

Eligibility Criteria

Inclusion Criteria:

all phototypes
only one of the following pigmentary conditions on the face: epidermal or mixed, mild to moderate melasma; mild to moderate acne-induced PIHP; solar lentigo
female patient of childbearing potential must use one of the reliable methods of contraception and agree not to change it during the study
patient agreeing not to be exposed to ultraviolet radiation (UV), natural (sun) or artificial (tanning salon), during the study

Exclusion Criteria:

female patient who gave birth less than 3 months prior to Day 0, who is pregnant, breast-feeding or who plans to become pregnant during the study
male patient with beard or facial hair, which would interfere with clinical evaluation or clinical procedure baseline)
patient with any inflammatory dermatosis of the face such as seborrheic dermatitis, rosacea etc.
severe melasma, dermal melasma
patient with facial pigmentary disorders other than those described in inclusion criteria
patient who has used topical depigmenting agents such as hydroquinone and derivatives, glycolic acid, kojic acid, retinoids and derivatives, azelaic acid, niacinamide within 1 month prior to Day 0/Baseline visit
patient who has used systemic treatments such as tranexamic acid and oral melatonin within 1 month prior to Day 0/Baseline visit;
patient who has used drugs inducing pigmentation such as tetracyclines, fluoroquinolones, antiepileptics within 1 month prior to Day 0/Baseline visit

Research Team

Sergio Schalka

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Evaluation of the Efficacy and Tolerability of the Tested Formula BID After 3 Months in the Treatment of Facial Hyperpigmentation of 3 Origins Melasma, Acne Induced Post-Inflammatory Hyperpigmentation and Solar Lentigo

On this page

AI-Summary

What this Trial Is About

Brief Title

Who Can Participate

Eligibility Criteria

Research Team

Not the Right Trial for You?

On this page

Who Can Participate

Eligibility Criteria